論文詳細ページ

Stem cells and neurological disease

Kwang Yul Cha

2018年度 年次大会-講演抄録 | 特別講演

学会講師 : Kwang Yul Cha

Abstract

The CHA Stem Cell Institute has revolutionized the practical use of human embryonic cells and various adult stem cells in clinical practice. Currently, human clinical trials are underway for the clinical use of stem cells and immune cells, including Age Related Macular Degeneration and Stargardt’ disease using hES-RPEs, Parkinson’s disease using fetal midbrain derived neuronal progenitor cells (hmNPCs), Cerebral Palsy (CP), Aging, and Stroke using umbilical cord blood cells (UCBCs), and various cancers using Natural Killer (NK) cells.

We have established that allogeneic umbilical cord blood has therapeutic potential for treating Cerebral Palsy (Stem Cells, 2013). In that study, we observed that UCB treatment ameliorated motor and cognitive dysfunction in children with CP undergoing active rehabilitation, accompanied by structural and metabolic changes in the brain.

We transplanted human fetal mesencephalic dopamine neuronal precursor cells (FMDNPCs) into 10 Parkinson’s disease and observed significant improvement in performance in PS and MTP measuring fine motor functions using CAPSIT-PD test. This observation and the analysis of the study is still ongoing.

CHA Stem Cell Institute has recently achieved considerable success in the generation of human embryonic like stem cells from dermal fibroblast via somatic cell nuclear transfer (SCNT), which marked SCNT as a valuable strategy for regenerative medicine (Cell Stem Cell, 2014). Using both SCNT development and hES-RPE (or neuronal) differentiation techniques CHA Hospital has investigated the effect of autologous transplantation of patient SCNT derived RPE which the first trial in the world to embark on the personalized stem cell medicine such as patient-tailored stem cell therapies for age-related macular degeneration and neural degenerative diseases.

In the present lecture, I will introduce the current status of our clinical applications using fetal, adult, embryonic and SCNT-based therapies, and discuss the future directions of stem cell application in regenerative medicine.

ページ先頭